Sidewinder Therapeutics vs Profluent Bio

Side-by-side comparison of AI visibility scores, market position, and capabilities

AI visibility is closely matched (36 vs 37)
Sidewinder Therapeutics logo

Sidewinder Therapeutics

EmergingBioTech

Oncology

Sidewinder Therapeutics raised $100M Series A in 2025 for its conditional activation platform that creates tumor-selective cancer drugs that only become active in the tumor microenvironment, reducing systemic toxicity.

AI VisibilityBeta
Overall Score
D36
Category Rank
#1 of 1
AI Consensus
51%
Trend
up
Per Platform
ChatGPT
47
Perplexity
44
Gemini
28

About

Sidewinder Therapeutics is developing conditionally activated cancer therapeutics — drugs engineered to remain inert in circulation and become pharmacologically active only when they reach the tumor microenvironment. The approach exploits the unique biochemical conditions of solid tumors (acidic pH, hypoxia, tumor-specific proteases) to trigger drug activation, allowing far higher doses to be delivered to tumors with dramatically reduced side effects in healthy tissues.

Full profile
Profluent Bio logo

Profluent Bio

EmergingBiotechnology

AI Protein Design

AI protein design company released OpenCRISPR-1, the first gene editor designed entirely by AI; raised $35M developing novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space beyond what evolution has produced.

AI VisibilityBeta
Overall Score
D37
Category Rank
#1 of 1
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
45
Perplexity
35
Gemini
38

About

Profluent Bio is an AI protein design company founded in 2022 by former Meta AI researcher Ali Madani, raising $35M in seed and Series A funding. The company trains large generative models on biological sequence data to design novel proteins with specific structural and functional properties, analogous to how large language models generate text. Profluent made scientific history in 2024 by publishing OpenCRISPR-1, the first gene editor designed entirely by AI rather than adapted from natural organisms, which the company released open source for non-commercial research. The platform enables design of novel enzymes, antibodies, and gene-editing tools by exploring protein sequence space far beyond what evolution has produced. Profluent works with pharmaceutical and agricultural biotechnology companies that need custom protein tools for research and therapeutic development. The company represents a fundamental advance in moving protein engineering from directed evolution and rational design toward generative AI-driven discovery.

Full profile

AI Visibility Head-to-Head

36
Overall Score
37
#1
Category Rank
#1
51
AI Consensus
69
up
Trend
up
47
ChatGPT
45
44
Perplexity
35
28
Gemini
38
31
Claude
37
40
Grok
31

Key Details

Category
Oncology
AI Protein Design
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Sidewinder Therapeutics
Oncology
Only Profluent Bio
AI Protein Design

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.